TransMedics Group, Inc. (TMDX)
TMDX Stock Price Chart
Explore TransMedics Group, Inc. interactive price chart. Choose custom timeframes to analyze TMDX price movements and trends.
TMDX Company Profile
Discover essential business fundamentals and corporate details for TransMedics Group, Inc. (TMDX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
2 May 2019
Employees
728.00
Website
https://www.transmedics.comCEO
Waleed H. Hassanein
Description
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
TMDX Financial Timeline
Browse a chronological timeline of TransMedics Group, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $0.51, while revenue estimate is $183.78m.
Earnings released on 5 May 2026
EPS came in at $0.30 falling short of the estimated $0.62 by -51.61%, while revenue for the quarter reached $173.93m , missing expectations by -0.29%.
Earnings released on 24 Feb 2026
EPS came in at $0.57 surpassing the estimated $0.41 by +39.02%, while revenue for the quarter reached $160.76m , beating expectations by +3.46%.
Earnings released on 29 Oct 2025
EPS came in at $0.66 surpassing the estimated $0.37 by +78.38%, while revenue for the quarter reached $143.82m , missing expectations by -7.46%.
Earnings released on 30 Jul 2025
EPS came in at $0.92 surpassing the estimated $0.48 by +91.67%, while revenue for the quarter reached $157.37m , beating expectations by +11.12%.
Earnings released on 8 May 2025
EPS came in at $0.70 surpassing the estimated $0.29 by +141.38%, while revenue for the quarter reached $143.54m , beating expectations by +16.32%.
Earnings released on 27 Feb 2025
EPS came in at $0.19 falling short of the estimated $0.22 by -13.64%, while revenue for the quarter reached $121.62m , beating expectations by +11.08%.
Earnings released on 28 Oct 2024
EPS came in at $0.12 falling short of the estimated $0.29 by -58.62%, while revenue for the quarter reached $108.76m , missing expectations by -3.04%.
Earnings released on 31 Jul 2024
EPS came in at $0.35 surpassing the estimated $0.21 by +66.67%, while revenue for the quarter reached $114.31m , beating expectations by +0.15%.
Earnings released on 30 Apr 2024
EPS came in at $0.35 surpassing the estimated $0.03 by +974.94%, while revenue for the quarter reached $96.85m , beating expectations by +15.44%.
Earnings released on 26 Feb 2024
EPS came in at $0.12 surpassing the estimated $0.02 by +500.00%, while revenue for the quarter reached $81.17m , beating expectations by +18.48%.
Earnings released on 6 Nov 2023
EPS came in at -$0.12 surpassing the estimated -$0.18 by +33.33%, while revenue for the quarter reached $66.43m , beating expectations by +35.05%.
Earnings released on 3 Aug 2023
EPS came in at -$0.03 surpassing the estimated -$0.15 by +80.00%, while revenue for the quarter reached $52.47m , beating expectations by +23.68%.
Earnings released on 1 May 2023
EPS came in at -$0.08 surpassing the estimated -$0.25 by +68.00%, while revenue for the quarter reached $41.55m , beating expectations by +15.27%.
Earnings released on 22 Feb 2023
EPS came in at -$0.21 surpassing the estimated -$0.28 by +25.00%, while revenue for the quarter reached $31.38m , beating expectations by +28.34%.
Earnings released on 3 Nov 2022
EPS came in at -$0.25 surpassing the estimated -$0.40 by +37.50%, while revenue for the quarter reached $25.68m , beating expectations by +36.07%.
Earnings released on 1 Aug 2022
EPS came in at -$0.41 falling short of the estimated -$0.32 by -28.12%, while revenue for the quarter reached $20.52m , beating expectations by +26.09%.
Earnings released on 3 May 2022
EPS came in at -$0.38 falling short of the estimated -$0.35 by -8.57%, while revenue for the quarter reached $15.88m , beating expectations by +64.37%.
Earnings released on 23 Feb 2022
EPS came in at -$0.46 falling short of the estimated -$0.43 by -6.98%, while revenue for the quarter reached $9.67m , beating expectations by +28.69%.
Earnings released on 9 Nov 2021
EPS came in at -$0.47 falling short of the estimated -$0.32 by -46.87%, while revenue for the quarter reached $5.37m , missing expectations by -33.87%.
Earnings released on 5 Aug 2021
EPS came in at -$0.39 falling short of the estimated -$0.27 by -44.44%, while revenue for the quarter reached $8.17m , beating expectations by +8.23%.
TMDX Stock Performance
Access detailed TMDX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
